A phase II clinical trial evaluating the safety and efficacy of durvalumab as first line therapy in advanced and metastatic non-small cell lung cancer patients with Eastern Cooperative Oncology Group performance status of 2

Khvaramze Shaverdashvili, Vincent Reyes, Hong Wang, Dhaval Mehta, Christopher Marsh, John K. Waas, Robert A. VanderWeele, Sajid M. Peracha, Hongmei Liang, Mark A. Socinski, David E. Gerber, Jonathan E. Dowell, Liza C. Villaruz